Mevastatin

Mevastatin

SCHEMBL1981408

CCC(C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@H]3C[C@@H](O)CC(=O)O3)[C@@H]21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 7/20 1.00
▸ HMGCR P04035 6/20 1.00
▸ LMNA P02545 5/20 1.00
▸ TSHR P16473 5/20 1.00
▸ SMN1; SMN2 Q16637 4/20 1.00
▸ HIF1A Q16665 4/20 1.00
▸ MEN1 O00255 3/20 1.00
▸ KMT2A Q03164 3/20 1.00
▸ ABCB11 O95342 3/20 1.00
▸ ALDH1A1 P00352 2/20 1.00
▸ CYP1A2 P05177 2/20 1.00
▸ MAPK1 P28482 1/20 1.00
▸ MTOR P42345 1/20 1.00
▸ HTT P42858 1/20 1.00
▸ NPSR1 Q6W5P4 1/20 1.00
▸ GMNN O75496 1/20 1.00
▸ TP53 P04637 1/20 1.00
▸ CYP2D6 P10635 1/20 1.00
▸ NFKB1 P19838 1/20 1.00
▸ BLM P54132 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mevastatin SCHEMBL13297669 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL8277387 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL13900408 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL23936978 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL1981409 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL23636208 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL21340588 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL21340571 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL21340628 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL15091134 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373609-B1 USE OF AMPHIPHILIC COMPOUNDS FOR CONTROLLED CRYSTALLIZATION OF STATINS AND STATIN INTERMEDIATES KRKA D D NOVO MESTO (SI) 2013-10-16 — — EP disclosed
EP-2327682-A1 Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates KRKA, D.D., Novo Mesto (SI) 2011-06-01 — — EP disclosed
Send feedback